CERT.NASDAQCertara, INC

Form 4: Certara Executive Nicolette D. Sherman Reports Stock Transactions

Sentiment:

SEC Form 4 Filing


Nicolette D. Sherman, Chief Human Resources Officer of Certara, Inc., reports the vesting and settlement of restricted stock units (RSUs) and associated tax withholding.

Summary

  • On April 1, 2024, Nicolette D. Sherman, Chief Human Resources Officer of Certara, Inc., reported transactions involving restricted stock units (RSUs).
  • 3,991 RSUs granted on April 1, 2022, vested and were settled.
  • 4,228 RSUs granted on April 1, 2023, also vested and were settled.
  • 1,252 and 1,326 shares were withheld to satisfy tax obligations at a price of $17.88.
  • Additionally, 15,190 RSUs were granted on April 1, 2024, which will vest in equal installments over the next three years.
  • Following these transactions, Sherman directly owns 24,358 shares of Certara common stock.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices. The vesting of RSUs is a positive sign of continued alignment with company goals. No immediate concerns are raised.

Positives

  • The vesting of RSUs indicates a continued alignment of the executive's interests with the company's performance.
  • The grant of additional RSUs (15,190) suggests ongoing commitment and incentivization for the executive.

Future Outlook

The remaining RSUs from the 2022, 2023 and 2024 grants are scheduled to vest and settle on April 1, 2025, April 1, 2026 and April 1, 2027.

Industry Context

This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies. It provides transparency regarding the equity-based compensation of key executives.

Comparison to Industry Standards

  • Executive compensation packages, including RSU grants, are common practice in publicly traded companies to align management's interests with those of shareholders.
  • The vesting schedules described are fairly standard, with one-third vesting annually over a three-year period.
  • Comparable companies in the pharmaceutical technology and services sector also utilize RSUs as part of their executive compensation plans.

Stakeholder Impact

  • Shareholders are informed about executive compensation practices.
  • Employees may be impacted by the tax implications of RSU vesting.

Key Dates

DateDescription
04/01/2022Grant date of 3,991 RSUs under the 2020 Incentive Plan.
03/31/2023One-third of the RSUs granted on April 1, 2022 vested and were settled.
04/01/2023Grant date of 4,228 RSUs under the 2020 Incentive Plan.
04/01/2024Vesting and settlement of RSUs granted on April 1, 2022 and April 1, 2023; Grant date of 15,190 RSUs.
04/01/2025Scheduled vesting and settlement of remaining RSUs from the April 1, 2022 grant and part of the April 1, 2023 and April 1, 2024 grants.
04/01/2026Scheduled vesting and settlement of remaining RSUs from the April 1, 2023 and April 1, 2024 grants.
04/01/2027Scheduled vesting and settlement of remaining RSUs from the April 1, 2024 grant.
04/03/2024Date of Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.